Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Deferred Taxes (2022 - 2026)

Bicycle Therapeutics (BCYC) has disclosed Deferred Taxes for 5 consecutive years, with -$241000.0 as the latest value for Q1 2026.

  • For Q1 2026, Deferred Taxes rose 81.69% year-over-year to -$241000.0; the TTM value through Mar 2026 reached $225000.0, up 103.9%, while the annual FY2025 figure was -$850000.0, 83.74% up from the prior year.
  • Deferred Taxes hit -$241000.0 in Q1 2026 for Bicycle Therapeutics, down from $843000.0 in the prior quarter.
  • Across five years, Deferred Taxes topped out at $7.3 million in Q3 2023 and bottomed at -$3.3 million in Q3 2024.
  • Average Deferred Taxes over 5 years is -$418941.2, with a median of -$767000.0 recorded in 2024.
  • Year-over-year, Deferred Taxes surged 810.06% in 2023 and then plummeted 266.67% in 2024.
  • Bicycle Therapeutics' Deferred Taxes stood at -$1.5 million in 2022, then skyrocketed by 80.83% to -$282000.0 in 2023, then tumbled by 266.67% to -$1.0 million in 2024, then skyrocketed by 181.53% to $843000.0 in 2025, then plummeted by 128.59% to -$241000.0 in 2026.
  • According to Business Quant data, Deferred Taxes over the past three periods came in at -$241000.0, $843000.0, and -$46000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.